One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial
Description
CONCLUSIONS: In a phase 2 study of non-hospitalized adults with mild-to-moderate COVID-19, oral camostat did not accelerate viral clearance nor time to symptom improvement, nor reduce hospitalizations or deaths. (Funded by the National Institutes of
